-
Hainan Haiyao Secures Exclusive Rights for AFT Pharmaceuticals’ Nutritional Products in China
•
China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced a significant licensing agreement with Australia-based AFT Pharmaceuticals Ltd (NZE: AFT, ASX: AFP). Through this agreement, Hainan Haiyao has obtained exclusive distribution rights to AFT Pharmaceuticals’ range of products in China, including Lipo-Sachets liposomal Vitamin C, Lipo-Sachets liposomal Vitamin D3, Ferro…
-
Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist
•
China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical studies for PaiEnJiaBin, a Category 1 chemical drug co-developed with the Shanghai Institute of Materia Medica. PaiEnJiaBin is a next-generation KCNQ potassium channel agonist, with no similar products approved globally, and is being developed to…
